FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1722587890> ?p ?o ?g. }

• W1722587890 endingPage "1610" @default.
• W1722587890 startingPage "1603" @default.
• W1722587890 abstract "Object Flow-diverting stents offer a novel treatment approach to intracranial aneurysms. Data regarding the incidence of acute procedure-related thromboembolic complications following deployment of the Pipeline Embolization Device (PED) remain scant. The authors sought to determine the rate of embolic events in a bid to identify potential risk factors and assess the role of platelet inhibition. Methods Data in all patients receiving a PED for treatment of an intracranial aneurysm were prospectively maintained in a database. Diffusion-weighted 3-T MRI was performed within 24 hours of PED deployment. The incident rate of procedural embolism was established, and univariate analysis was then performed to determine any associations of embolic events with measured variables. The degree of platelet inhibition in response to aspirin and clopidogrel was evaluated by challenging the platelet samples with arachidonic acid and adenosine diphosphate, respectively, and then performing formal light transmission platelet aggregometry. Results Twenty-three patients with 26 aneurysms were eligible for inclusion in the study. Thirty-one PEDs were deployed in 25 procedures. All ischemic lesions detected on diffusion-weighted 3-T MRI were identified as embolic based on their location and distribution, with none appearing to be due to perforator artery occlusion. Procedural embolic events were found in the target parent vessel territory in 13 (52%) of 25 procedures, with no patients harboring lesions contralateral to the deployed PED. The number of embolic events per procedure ranged from 3 to 16, with a mean of 5.4. There was no significant difference between cases with and without procedural embolism in platelet inhibition by aspirin (mean 15% vs 12% residual activation; p = 0.28), platelet inhibition by clopidogrel (mean 41% vs 41% residual activation; p = 0.98), or intraprocedural heparin-induced anticoagulation (mean activated clotting time 235 seconds vs 237 seconds; p = 0.81). By multivariate analysis, the authors identified larger aneurysm size (p = 0.03) as the single variable significantly associated with procedural embolism. There was no significant relationship between aneurysm size and the number of embolic events (p = 0.32) or the total burden of the embolism lesion area (p = 0.53). Conclusions Acute embolism following use of the PED for treatment of intracranial aneurysms is more common than hypothesized. The only identifiable risk factor for embolism appears to be greater aneurysm size, perhaps indicating significant disturbed flow across the aneurysm neck with ingress and egress through the PED struts. The strength of antiplatelet therapy, as measured by residual platelet aggregation, did not appear to be associated with cases of procedural embolism. Further work is needed to determine the implications of these findings and whether anticoagulation regimens can be altered to lower the rate of complications following PED deployment." @default.
• W1722587890 created "2016-06-24" @default.
• W1722587890 creator A5014696414 @default.
• W1722587890 creator A5055424750 @default.
• W1722587890 creator A5075568894 @default.
• W1722587890 creator A5076951329 @default.
• W1722587890 date "2013-12-01" @default.
• W1722587890 modified "2023-10-14" @default.
• W1722587890 title "Effect of antiplatelet therapy on thromboembolism after flow diversion with the Pipeline Embolization Device" @default.
• W1722587890 cites W1794151345 @default.
• W1722587890 cites W1831701488 @default.
• W1722587890 cites W1972121983 @default.
• W1722587890 cites W1987143431 @default.
• W1722587890 cites W1989028385 @default.
• W1722587890 cites W1997534509 @default.
• W1722587890 cites W2007206486 @default.
• W1722587890 cites W2019068107 @default.
• W1722587890 cites W2023921808 @default.
• W1722587890 cites W2036974533 @default.
• W1722587890 cites W2045428665 @default.
• W1722587890 cites W2049457167 @default.
• W1722587890 cites W2096945996 @default.
• W1722587890 cites W2099145382 @default.
• W1722587890 cites W2108876549 @default.
• W1722587890 cites W2113516725 @default.
• W1722587890 cites W2121150448 @default.
• W1722587890 cites W2126679877 @default.
• W1722587890 cites W2132511760 @default.
• W1722587890 cites W2138004881 @default.
• W1722587890 cites W2138837775 @default.
• W1722587890 cites W2149285581 @default.
• W1722587890 cites W2149465085 @default.
• W1722587890 cites W2150433179 @default.
• W1722587890 cites W2153528438 @default.
• W1722587890 cites W2157833432 @default.
• W1722587890 cites W2165620610 @default.
• W1722587890 cites W2968751749 @default.
• W1722587890 cites W4230537981 @default.
• W1722587890 doi "https://doi.org/10.3171/2013.7.jns122178" @default.
• W1722587890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23971953" @default.
• W1722587890 hasPublicationYear "2013" @default.
• W1722587890 type Work @default.
• W1722587890 sameAs 1722587890 @default.
• W1722587890 citedByCount "52" @default.
• W1722587890 countsByYear W17225878902014 @default.
• W1722587890 countsByYear W17225878902015 @default.
• W1722587890 countsByYear W17225878902016 @default.
• W1722587890 countsByYear W17225878902017 @default.
• W1722587890 countsByYear W17225878902018 @default.
• W1722587890 countsByYear W17225878902019 @default.
• W1722587890 countsByYear W17225878902020 @default.
• W1722587890 countsByYear W17225878902021 @default.
• W1722587890 countsByYear W17225878902022 @default.
• W1722587890 countsByYear W17225878902023 @default.
• W1722587890 crossrefType "journal-article" @default.
• W1722587890 hasAuthorship W1722587890A5014696414 @default.
• W1722587890 hasAuthorship W1722587890A5055424750 @default.
• W1722587890 hasAuthorship W1722587890A5075568894 @default.
• W1722587890 hasAuthorship W1722587890A5076951329 @default.
• W1722587890 hasBestOaLocation W17225878901 @default.
• W1722587890 hasConcept C126322002 @default.
• W1722587890 hasConcept C126838900 @default.
• W1722587890 hasConcept C141071460 @default.
• W1722587890 hasConcept C164705383 @default.
• W1722587890 hasConcept C2776035437 @default.
• W1722587890 hasConcept C2777185221 @default.
• W1722587890 hasConcept C2777628954 @default.
• W1722587890 hasConcept C2777849778 @default.
• W1722587890 hasConcept C42219234 @default.
• W1722587890 hasConcept C71924100 @default.
• W1722587890 hasConceptScore W1722587890C126322002 @default.
• W1722587890 hasConceptScore W1722587890C126838900 @default.
• W1722587890 hasConceptScore W1722587890C141071460 @default.
• W1722587890 hasConceptScore W1722587890C164705383 @default.
• W1722587890 hasConceptScore W1722587890C2776035437 @default.
• W1722587890 hasConceptScore W1722587890C2777185221 @default.
• W1722587890 hasConceptScore W1722587890C2777628954 @default.
• W1722587890 hasConceptScore W1722587890C2777849778 @default.
• W1722587890 hasConceptScore W1722587890C42219234 @default.
• W1722587890 hasConceptScore W1722587890C71924100 @default.
• W1722587890 hasIssue "6" @default.
• W1722587890 hasLocation W17225878901 @default.
• W1722587890 hasLocation W17225878902 @default.
• W1722587890 hasOpenAccess W1722587890 @default.
• W1722587890 hasPrimaryLocation W17225878901 @default.
• W1722587890 hasRelatedWork W2080681036 @default.
• W1722587890 hasRelatedWork W2130615932 @default.
• W1722587890 hasRelatedWork W2160363106 @default.
• W1722587890 hasRelatedWork W2351182631 @default.
• W1722587890 hasRelatedWork W2384505200 @default.
• W1722587890 hasRelatedWork W2399265450 @default.
• W1722587890 hasRelatedWork W2411614779 @default.
• W1722587890 hasRelatedWork W2442397302 @default.
• W1722587890 hasRelatedWork W3094206399 @default.
• W1722587890 hasRelatedWork W2527719101 @default.
• W1722587890 hasVolume "119" @default.
• W1722587890 isParatext "false" @default.
• W1722587890 isRetracted "false" @default.

• next